Bausch & LombBLCO -2.99%77 ROC (Joel Greenblatt) % is 5.28% as of Mar. 2026, which is 60% below its 10-year median of 13.14. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.65 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 839 Medical Devices & Instruments companies, Bausch & Lomb ranks better than 56.38% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Bausch & Lomb's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.28%.
The historical rank and industry rank for Bausch & Lomb's ROC (Joel Greenblatt) % or its related term are showing as below:
BLCO'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.32 Med: 13.14 Max: 31.6
Current: 9.09
During the past 8 years, Bausch & Lomb's highest ROC (Joel Greenblatt) % was 31.60%. The lowest was 4.32%. And the median was 13.14%.
BLCO's ROC (Joel Greenblatt) % is ranked better than 56.38% of 839
companies
in the Medical Devices & Instruments industry
Industry Median: 3.94
vs BLCO: 9.09
Bausch & Lomb's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -26.70% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Bausch & Lomb ROC (Joel Greenblatt) % Related Terms
Bausch & Lomb ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Bausch & Lomb's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLCO vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 5.28% mean?
Bausch & Lomb (BLCO) has a ROC (Joel Greenblatt) % of 5.28% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Bausch & Lomb and its competitors. This is 60% below median its historical median of 13.14. Over the past decade, Bausch & Lomb's ROC (Joel Greenblatt) % has ranged from 4.32 to 31.60. According to the industry distribution chart, Bausch & Lomb ranks #366 out of 839 companies in the Medical Devices & Instruments industry, placing it in the top 43.6%.
Is Bausch & Lomb's ROC (Joel Greenblatt) % too high?
Bausch & Lomb's current ROC (Joel Greenblatt) % of 5.28% is 60% below median its 10-year median of 13.14. Over the past 10 years, this metric has ranged from a low of 4.32 to a high of 31.60. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 3.94. Bausch & Lomb's value of 5.28% is 34% above this industry median. Based on the distribution chart, Bausch & Lomb ranks #366 out of 839 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #366 out of 839 companies for ROC (Joel Greenblatt) %. This puts Bausch & Lomb in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 3.94. Bausch & Lomb's value of 5.28% is 34% above this benchmark. Historically, Bausch & Lomb's own ROC (Joel Greenblatt) % has ranged from 4.32 to 31.60 over the past decade. While the company's 10-year median is 13.14 vs. the industry median of 3.94, Bausch & Lomb has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 3.94, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch & Lomb's current ROC (Joel Greenblatt) % of 5.28% is 34% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Bausch & Lomb and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 3.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch & Lomb's current ROC (Joel Greenblatt) % is 5.28%, which is 60% below median its own 10-year median of 13.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.65, compared to a current price of $16.23 — trading 13% below its estimated fair value. The current ROC (Joel Greenblatt) % is 5.28%, which is 60% below median its 10-year median of 13.14 and 34% above the Medical Devices & Instruments industry median of 3.94. Bausch & Lomb's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current ROC (Joel Greenblatt) % is 5.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of $16.23 is trading 13% below its estimated GF Value™ of $18.65.
GuruFocus considers Bausch & Lomb to be Modestly Undervalued.
Key valuation signals for BLCO:
ROC (Joel Greenblatt) %: 5.28% (60% below median its 10-year median of 13.14)
GF Value™: $18.65 vs. price of $16.23 (13% below fair value)
Industry Position: 34% above the Medical Devices & Instruments median (#366 of 839)
No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score
Get the complete analysis for BLCO
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLCO has been successfully added to your 
